Review

Use of Bevacizumab in the Treatment of Corneal Neovascularization

10.4274/tjo.85530

  • Tuba Çelik
  • Mustafa Kösker

Received Date: 16.10.2013 Accepted Date: 30.06.2014 Turk J Ophthalmol 2015;45(1):31-36

Corneal neovascularization is a serious condition resulting in various degrees of vision loss. The abnormal vascularization blocks the light depending on the corneal scarring, thus it reduces the visual acuity. Corneal neovascularization occurs as a result of shifting the balance between the angiogenic and the antiangiogenic factors on behalf of the angiogenic factors. Vascular endothelial growth factor (VEGF) is the primary mediator of angiogenesis. Anti-VEGF agents are widely used in the treatment of neovascular age-related macular degeneration, diabetic retinopathy, macular edema, neovascular glaucoma, and the other neovascular diseases. These agents are also effective in the treatment of corneal neovascularization. Herein, we discuss the most known anti-VEGF agent bevacizumab and its administration routes, the efficiency and the complications.

Keywords: Corneal neovascularization, anti-VEGF, bevacizumab

Full Text (Turkish)